39614-82-9

Upstream product

• 619-19-2 2-hydroxy-4-nitrobenzoic acid 

Downstream Products

• 858479-10-4 2-hydroxy-4-nitro-benzoic acid thiazol-2-ylamide 
• 857756-46-8 2-hydroxy-4-nitro-benzoic acid pyrimidin-2-ylamide 
• 860510-41-4 2-hydroxy-4-nitro-benzoic acid propyl ester 
• 873401-46-8 2-hydroxy-4-nitro-benzoic acid-(5-methyl-[1,3,4]thiadiazol-2-ylamide) 
• 860510-11-8 2-hydroxy-4-(2-hydroxy-4-nitro-benzoylamino)-benzoic acid ethyl ester 
• 197566-34-0 2-hydroxy-4-nitro-benzoic acid anilide 
• 101265-99-0 2-hydroxy-4-nitro-thiobenzoic acid S-(2-diethylamino-ethyl ester) 
• 874501-03-8 benzyl 2-hydroxy-4-nitrobenzoate 
• 106838-57-7 2-hydroxy-4-nitro-benzoic acid-(3-acetylamino-phenyl ester) 
• 21525-02-0 Butan-1,4-diol-bis-(4-amino-salicylat) 
• 21525-04-2 Hexan-1,6-diol-bis-(4-amino-salicylat) 
• 17208-94-5 Heptan-1,7-diol-bis-(4-amino-salicylat) 
• 21525-05-3 Octan-1,8-diol-bis-(4-amino-salicylat) 
• 21525-06-4 Nonan-1,9-diol-bis-(4-amino-salicylat) 

Relevant academic research and scientific papers

Compounds with neuroprotective effect, and preparation method and application thereof

The invention relates to compounds with a neuroprotective effect, and a preparation method and application thereof. Specifically, the compounds disclosed by the invention have a structure as shown in a formula I, and the definitions of all groups and subs

Design, synthesis, and biological evaluation of 3′,4′,5′-trimethoxy evodiamine derivatives as potential antitumor agents

A series of compounds bearing 3′,4′,5′-trimethoxy module into the core structure of evodiamine were designed and synthesized. The synthesized compounds were screened in vitro for their antitumor potential. MTT results showed that compounds 14a–14c and 14i–14j had significant effects, with compound 14h being the most prominent, with an IC50 value of 3.3 ± 1.5?μM, which was lower than evodiamine and 5-Fu. Subsequent experiments further confirmed that compound 14h could inhibit cell proliferation and migration, and induce G2/M phase arrest to inhibit the proliferation of HGC-27 cells, which is consistent with the results of the cytotoxicity experiment. Besides, 14h could inhibit microtubule assembly and might kill tumor cells by inhibiting VEGF and glycolysis. All experimental results indicate that compound 14h might be a potential drug candidate for the treatment of gastric cancer and was worthy of further study.

NOVEL NEUROTRYPSIN INHIBITORS

The invention relates to novel acylamino-hydroxy-benzamides of formula (I), wherein R1 is phenyl substituted by phenyl, phenoxy, phenylamino or heteroaryl, all optionally further substituted; bicyclic aryl, monocyclic heteroaryl substituted by

2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS

The invention provides compounds of formula (I), and pharmaceutically acceptable salts thereof wherein: Rl, R2, R3, R4, R5, R6, R7, X and X1 are as defined herein. These compounds are useful in the manufacture of medicaments for use in the prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.

RADIOHALOGENATED BENZAMIDE DERIVATIVES AND THEIR USE IN TUMOR DIAGNOSIS AND TUMOR THERAPY

This invention relates to new radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy. The radiohalogenated benzamide derivatives according to the invention exhibit novel and especially advantageous properties, in particular with respect to tumor concentration and retardation, liver concentration and blood accumulation. The radiation-therapy doses to be achieved in the tumor, compared to healthy body tissue, are advantageous for the compounds according to the invention.